CANCER CHEMOTHERAPEUTIC AGENTS;CARRIER MOLECULES FOR CISPLATIN In the past few years, peripheral-type benzodiazepine receptors (PBZR) have been identified - initially as binding sites in peripheral tissues - with a noticeably different spectrum of drug activity than that of the more celebrated central-type receptor ligands (e.g. Valium. It has been found that the density of these receptors is increased both in ovarian carcinomas (as compared with benign ovarian tumors and with normal ovaries), and in human gliomas. This property has been used for PET imaging of human brain tumors using 11C radiolabelled, selective peripheral legends. It has been shown that the peripherally active ligands inhibited the growth of human melanoma cells and were able to potentiate the antiproliferative activity of recombinant human interferons. The initial aim of this proposal is to tests the hypothesis that PBZR ligands can be used, not only as anti-cancer agents in their own right, but as carrier moleculs to target cancerous organs (high PBZR density) with known chemotherapeutic agents which have limited utility due to poor tissue distribution (e.g. cisplatin). The achievement of this goal requires the synthesis and biological evaluation of chelates of platinum with PBZR ligands. Initially, it is intended to use a 5-(2-pyridyl) substituted-1,4-benzodiazepine as the substrate for chelation with the platinum reagent. This should demonstrate the viability of the proposal, although other, structurally different PBZR ligands, can be envisaged as agents for chelation with, perhaps, differing bioavailabilities. Initial testing will be carried out by our collaborators at the NIH. Ligands that are active at the PBZR will be submitted to the Fox-Chase Cancer institute for cytotoxicity evaluation an to the NCI for subsequent in vivo evaluation.

Project Start
1998-07-01
Project End
1999-12-31
Budget Start
Budget End
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Rutgers University
Department
Type
DUNS #
130029205
City
Newark
State
NJ
Country
United States
Zip Code
07102
Baykal, Ahmet; Chakraborty, Sumit; Dodoo, Afua et al. (2006) Synthesis with good enantiomeric excess of both enantiomers of alpha-ketols and acetolactates by two thiamin diphosphate-dependent decarboxylases. Bioorg Chem 34:380-93
Mattson, Brandi J; Williams, Sharon E; Rosenblatt, Jay S et al. (2003) Preferences for cocaine- or pup-associated chambers differentiates otherwise behaviorally identical postpartum maternal rats. Psychopharmacology (Berl) 167:1-8
Gilchrist, Alan L; Annan Jr, Vidal (2002) Articulation effects in lightness: historical background and theoretical implications. Perception 31:141-50
Vathy, Ilona; Komisaruk, Barry R (2002) Differential effects of prenatal morphine exposure on analgesia produced by vaginocervical stimulation or systemic morphine administration in adult rats. Pharmacol Biochem Behav 72:165-70
Mattson, B J; Williams, S; Rosenblatt, J S et al. (2001) Comparison of two positive reinforcing stimuli: pups and cocaine throughout the postpartum period. Behav Neurosci 115:683-94
Duque, A; Balatoni, B; Detari, L et al. (2000) EEG correlation of the discharge properties of identified neurons in the basal forebrain. J Neurophysiol 84:1627-35
Komisaruk, B R; Rosenblatt, J S; Barona, M L et al. (2000) Combined c-fos and 14C-2-deoxyglucose method to differentiate site-specific excitation from disinhibition: analysis of maternal behavior in the rat. Brain Res 859:262-72
Caba, M; Komisaruk, B R; Beyer, C (1998) Analgesic synergism between AP5 (an NMDA receptor antagonist) and vaginocervical stimulation in the rat. Pharmacol Biochem Behav 61:45-8
Sansone, G R; Bianca, R; Cueva-Rolon, R et al. (1997) Cardiovascular responses to vaginocervical stimulation in the spinal cord-transected rat. Am J Physiol 273:R1361-6
Burroughs, L F; Fiber, J M; Swann, J M (1996) Neuropeptide Y in hamster limbic nuclei: lack of colocalization with substance P. Peptides 17:1053-62

Showing the most recent 10 out of 15 publications